Systematic Review of Single-Fraction Stereotactic Body Radiation Therapy for Early Stage Non-Small-Cell Lung Cancer and Lung Oligometastases: How to Stop Worrying and Love One and Done

Bartl, AJ; Mahoney, M; Hennon, MW; Yendamuri, S; Videtic, GMM; Stephans, KL; Siva, S; Farrugia, MK; Ma, SJ; Singh, AK

Author(s): Bartl, AJ; Mahoney, M; Hennon, MW; Yendamuri, S; Videtic, GMM; Stephans, KL; Siva, S; Farrugia, MK; Ma, SJ; Singh, AK;
Details: Publication Year 2022-02-03,Volume 14,Issue #3,Page 790
Journal Title: Cancers
Publication Type: Review
Abstract: Adoption of single-fraction lung stereotactic body radiation therapy (SBRT) for patients with medically inoperable early stage non-small-cell lung cancer (NSCLC) or oligometastatic lung disease, even during the coronavirus disease 2019 (COVID-19) pandemic, was limited despite encouraging phase II trial results. Barriers to using single-fraction SBRT may include lack of familiarity with the regimen and lack of clarity about the expected toxicity. To address these concerns, we performed a systematic review of prospective literature on single-fraction SBRT for definitive treatment of early stage and oligometastatic lung cancer. A PubMed search of prospective studies in English on single-fraction lung SBRT was conducted. A systematic review was performed of the studies that reported clinical outcomes of single-fraction SBRT in the treatment of early stage non-small-cell lung cancer and lung oligometastases. The current prospective literature including nine trials supports the use of single-fraction SBRT in the definitive treatment of early stage peripheral NSCLC and lung oligometastases. Most studies cite local control rates of >90%, mild toxicity profiles, and favorable survival outcomes. Most toxicities reported were grade 1-2, with grade >/=3 toxicity in 0-17% of patients. Prospective trial results suggest potential consideration of utilizing single-fraction SBRT beyond the COVID-19 pandemic.
Keywords: Nsclc; Sabr; Sbrt; lung; lung oligometastases; single fraction
Department(s): Radiation Oncology
PubMed ID: 35159057
Publisher's Version: https://doi.org/10.3390/cancers14030790
Open Access at Publisher's Site: https://doi.org/10.3390/cancers14030790
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-10-04 07:33:07

Last Modified: 2024-10-04 07:34:42